In Section A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to recognize Harmless dosing regimen. Added contributors will likely be enrolled for the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Phase C, https://hafizp700isc2.blgwiki.com/user